Moderna hantavirus vaccine enters Phase 1 trials by 2026-12-31

Market overview

Moderna’s hantavirus vaccine development is in early stages. Given the recent surge in stock price and urgency from public health concerns, accelerated trials are likely.

earnings prediction market

Implied probability (Yes)

70%

Source: user-generated

More earnings markets

• Flex's AI video revenue surpasses $1B in 2026 — 72% Yes
• Anthropic's valuation exceeds $1 trillion by 2027-Q1 — 70% Yes
• Pharmaceutical companies' U.S. revenue growth slows by 5% in 2027 — 75% Yes
• Broadcom revenue exceeds $60 billion in fiscal 2026 — 68% Yes
• Major bank reports mark-to-market losses on bond short by Q4 2026 — 75% Yes
• Under Armour rebounds to profitability by Q4 2026 — 60% Yes
• Lovable hits $1 billion annualized revenue by March 2027 — 68% Yes
• Hallmark's greeting card revenue increases by 5% in FY2026 — 70% Yes

Browse all earnings markets →